c-MET pathway activation plays an essential role in the development/progression and drug-resistance of many cancers [21], and can be caused by MET protein and/or gene overexpression, gene amplification, MET exon- 14 skipping mutations and/or aberrant paracrine/autocrine HGF production [22]. Here, MET is linked to cancer.